Transplantation and Cellular Therapy Meetings | Conference

KD025 Induces Impressive Activity in cGVHD

February 25th 2020

The selective ROCK2 inhibitor KD025 induced clinical responses in approximately two-thirds of patients with chronic graft-versus-host disease, including complete responses in 3 patients.

Pasireotide Does Not Decrease Risk of GI Toxicity or Acute GVHD Following HSCT

February 24th 2020

Anthony D. Sung, MD, discusses the findings from the phase II trial of pasireotide as a method to prevent gastrointestinal toxicity and acute graft-versus-host-disease in patients who undergo allogeneic hematopoietic stem cell transplant.

Dr. Maloney on the Value of CAR T Cells in Relapsed/Refractory Aggressive Lymphomas

February 23rd 2020

David G. Maloney, MD, PhD, discusses the value of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive lymphomas.

Narsoplimab Emerging as Treatment Option for TA-TMA

February 23rd 2020

Narsoplimab (OMS721) is advancing through the therapy pipeline as a novel treatment option for patients with transplant-associated thrombotic microangiopathy.

KTE-X19 Poised to Have Promising Future in MCL Paradigm

February 23rd 2020

David Miklos, MD, discusses the results from the ZUMA-2 trial evaluating KTE-X19 in patients with relapsed/refractory mantle cell lymphoma.

Dr. Dandoy on Overcoming Challenges with TA-TMA

February 23rd 2020

Christopher E. Dandoy, MD, MSc, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy. The primary challenges are diagnosing and identifying TA-TMA in patients.

"Off-the-Shelf" CAR T-Cell Therapy Shows Promise in Non-Hodgkin Lymphoma

February 22nd 2020

An “off-the-shelf” Epstein Barr-virus–specific cytotoxic lymphocyte CAR product derived from cells harvested from third-party donors induced a 100% response rate in adult and pediatric patients with relapsed/refractory non-Hodgkin lymphoma.

Dr. Sauter on CAR T Cells in Real-World Patients With Hematologic Malignancies

February 22nd 2020

Craig Sauter, MD, discusses the anecdotal observational data in real-world patients with hematologic malignancies who received chimeric antigen receptor T-cell therapy.

Expert Highlights Remaining Diagnostic Challenges With TA-TMA

February 22nd 2020

Sergio A. Giralt, MD, discusses the diagnostic challenges of transplant-associated thrombotic microangiopathy.

Axi-Cel Toxicity in LBCL May Be Alleviated With Earlier Steroid Use

February 22nd 2020

Early steroid intervention has the potential to reduce the severity of adverse events associated with axicabtagene ciloleucel in patients with refractory large B-cell lymphoma, according to an analysis of the phase I/II ZUMA-1 trial.

Conditioning Therapy With Iomab-B Leads to High Transplant Rate in Active AML

February 21st 2020

Iodine (131I) apamistamab (Iomab-B) conditioning induced a complete remission in 84% (31/38) of patients with active acute myeloid leukemia, who were then able to receive allogeneic hematopoietic stem cell transplant, according to preliminary results from the phase III SIERRA trial.

Dr. Bachier on the Toxicity Profile of Liso-Cel

February 21st 2020

Carlos R. Bachier, MD, discusses the toxicity profile of lisocabtagene maraleucel that has been observed in 3 ongoing clinical trials in relapsed/refractory large B-cell non-Hodgkin lymphoma.

Dr. Kumar on the Role of Stem Cell Mobilization in Multiple Myeloma

February 21st 2020

Shaji K. Kumar, MD, discusses the role of stem cell mobilization in multiple myeloma. This is important in patients with myeloma who are eligible for stem cell transplantation.

Ruxolitinib Efficacy in Chronic GVHD Highlighted Across Age Groups

February 21st 2020

Ruxolitinib is an effective and well-tolerated treatment in the refractory setting for patients with chronic graft-versus-host disease, regardless of age.

Liso-Cel Analysis Shows Feasibility of Outpatient CAR T-Cell Therapy

February 20th 2020

Outpatient administration of CAR T-Cell therapy is safe and effective, according to an analysis of 3 studies of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr. Jain on Hematopoietic Recovery Following CAR T-Cell Therapy

February 20th 2020

Tania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.

Iomab-B Shows Promise as Novel Conditioning for HSCT in AML

February 25th 2019

More than 90% of older patients with relapsed/refractory acute myeloid leukemia had successful engraftment of allogeneic hematopoietic stem cell transplant preceded by novel conditioning with an iodinated CD45-targeted antibody.

CD30 CAR T Cells Active in Hodgkin Lymphoma

February 25th 2019

Chimeric antigen receptor T cells targeting CD30 proved to be safe and active in relapsed/refractory Hodgkin lymphoma.

Dr. Shaughnessy Discusses Stem Cell Mobilization in Lymphomas

February 25th 2019

Paul J. Shaughnessy, MD, discusses stem cell mobilization in patients with lymphomas.

Herpes Zoster Vaccine Elicits Robust Immune Response in HSCT Patients

February 25th 2019

Two doses of adjuvanted recombinant zoster vaccine following autologous hematopoietic stem cell transplant led to rapid and durable cell-mediated immune responses, results from a subgroup analysis of a large randomized, placebo-controlled trial showed.1